Pyxis Oncology (PYXS) Accumulated Expenses (2020 - 2026)

Pyxis Oncology (PYXS) has reported Accumulated Expenses for 6 consecutive years, with $8.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses fell 24.77% year-over-year to $8.6 million; the TTM figure through Dec 2025 stood at $8.6 million (down 24.77% YoY), while the FY2025 annual figure was $8.6 million, down 24.77% from the prior year.
• Accumulated Expenses improved to $8.6 million in Q4 2025 per PYXS's latest filing, from $8.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.1 million in Q1 2022 and bottomed at $4.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $9.4 million across 5 years, with a median of $8.3 million in 2025.
• Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 230.1% — and 2023, when it slumped 62.86%.
• Pyxis Oncology's Accumulated Expenses stood at $6.6 million in 2021, then plunged by 35.71% to $4.2 million in 2022, then grew by 23.15% to $5.2 million in 2023, then jumped by 117.88% to $11.4 million in 2024, then dropped by 24.77% to $8.6 million in 2025.
• Business Quant data shows PYXS's Accumulated Expenses at $8.6 million in Q4 2025, $8.0 million in Q3 2025, and $6.7 million in Q2 2025.